An open-label, phase 2 trial of RPI.4610 (angiozyme) in the treatment of metastatic breast cancer

Cancer ◽

10.1002/cncr.26730 ◽

2012 ◽

Vol 118 (17) ◽

pp. 4098-4104 ◽

Author(s):

Phuong Khanh Morrow ◽

Rashmi K. Murthy ◽

Joe D. Ensor ◽

Gilad S. Gordon ◽

Kim A. Margolin ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Metastatic Breast ◽

Phase 2 ◽

Phase 2 Trial ◽

Open Label Phase

Download Full-text

PO58 EFFICACY AND SAFETY OF FIRST-LINE EVEROLIMUS PLUS LETROZOLE IN ER+ HER2− METASTATIC BREAST CANCER: A MULTI-CENTER, OPEN-LABEL, PHASE 2 TRIAL BOLERO-4

10.1016/s0960-9776(13)70072-9 ◽

2013 ◽

Vol 22 ◽

pp. S39-S40

Author(s):

Sergio Azevedo ◽

Thomas Bachelo ◽

William Gradishar ◽

Francois Ringeisen ◽

Thomas Brechenmacher ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Metastatic Breast ◽

Phase 2 ◽

Efficacy And Safety ◽

Phase 2 Trial ◽

Open Label Phase

Download Full-text

Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: A multicentre, open-label, randomised phase 2 trial

European Journal of Cancer ◽

10.1016/j.ejca.2014.10.008 ◽

2014 ◽

Vol 50 (18) ◽

pp. 3077-3088 ◽

Author(s):

S.W. Lam ◽

S.M. de Groot ◽

A.H. Honkoop ◽

A. Jager ◽

A.J. ten Tije ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Metastatic Breast ◽

Line Treatment ◽

Phase 2 ◽

Phase 2 Trial ◽

Locally Recurrent ◽

First Line Treatment

Download Full-text

CYP2D6 Genotype-Guided Tamoxifen Dosing in Hormone Receptor-Positive Metastatic Breast Cancer (TARGET-1): A Randomized, Open-Label, Phase 2 Study

SSRN Electronic Journal ◽

10.2139/ssrn.3365080 ◽

2019 ◽

Author(s):

Kenji Tamura ◽

Chiyo K. Imamura ◽

Toshimi Takano ◽

Shigehira Saji ◽

Takeharu Yamanaka ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Hormone Receptor ◽

Metastatic Breast ◽

Phase 2 ◽

Hormone Receptor Positive ◽

Phase 2 Study ◽

Open Label Phase

Download Full-text

Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial

The Lancet Oncology ◽

10.1016/s1470-2045(19)30565-0 ◽

2019 ◽

Vol 20 (12) ◽

pp. 1750-1759 ◽

Author(s):

Yeon Hee Park ◽

Tae-Yong Kim ◽

Gun Min Kim ◽

Seok Yun Kang ◽

In Hae Park ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Metastatic Breast ◽

Premenopausal Women ◽

Gonadotropin Releasing Hormone ◽

Phase 2 ◽

Gonadotropin Releasing Hormone Agonist ◽

Phase 2 Trial ◽

Hormone Receptor Positive

Download Full-text

N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group (NCCTG) Trial

Annals of Oncology ◽

10.1093/annonc/mdp328 ◽

2010 ◽

Vol 21 (3) ◽

pp. 493-497 ◽

Author(s):

W.W. Tan ◽

D.W. Hillman ◽

M. Salim ◽

D.W. Northfelt ◽

D.M. Anderson ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Treatment Group ◽

Cancer Treatment ◽

Metastatic Breast ◽

Phase 2 ◽

North Central ◽

Irinotecan Hydrochloride ◽

Download Full-text

Abstract PD3-06: Updated results from DESTINY-breast01, a phase 2 trial of trastuzumab deruxtecan (T-DXd ) in HER2 positive metastatic breast cancer

10.1158/1538-7445.sabcs20-pd3-06 ◽

2021 ◽

Author(s):

Shanu Modi ◽

Cristina Saura ◽

Toshinari Yamashita ◽

Yeon Hee Park ◽

Sung-Bae Kim ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Metastatic Breast ◽

Phase 2 ◽

Her2 Positive ◽

Download Full-text

Correction to: N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group (NCCTG) Trial

Annals of Oncology ◽

10.1093/annonc/mdx811 ◽

2018 ◽

Vol 29 (10) ◽

pp. 2150

Author(s):

W.W. Tan ◽

D.W. Hillman ◽

M. Salim ◽

D.W. Northfelt ◽

D.M. Anderson ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Treatment Group ◽

Cancer Treatment ◽

Metastatic Breast ◽

Phase 2 ◽

North Central ◽

Irinotecan Hydrochloride ◽

Download Full-text

Abstract OT3-06-01: SHERBOC: A double-blind, placebo-controlled, phase 2 trial of seribantumab (MM-121) plus fulvestrant in postmenopausal women with hormone receptor-positive, heregulin positive, HER2 negative metastatic breast cancer whose disease progressed after prior systemic therapy

10.1158/1538-7445.sabcs17-ot3-06-01 ◽

2018 ◽

Author(s):

PA Kaufman ◽

M Pipas ◽

GJ Finn ◽

SE Mathews ◽

H Zhang ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Systemic Therapy ◽

Metastatic Breast ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo ◽

Phase 2 Trial ◽

Hormone Receptor Positive ◽

Prior Systemic Therapy

Download Full-text

Abstract P4-14-22: A single-center, open-label phase 1b study of entinostat, and lapatinib alone, and in combination with and trastuzumab in patients with HER2+ metastatic breast cancer after progression on trastuzumab

10.1158/1538-7445.sabcs15-p4-14-22 ◽

2016 ◽

Author(s):

B Lim ◽

S Jackson ◽

RH Alvarez ◽

NK Ibrahim ◽

JS Willey ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Metastatic Breast ◽

Single Center ◽

Open Label Phase ◽

Download Full-text

Abstract P6-16-03: Phase 2 trial of everolimus and/or trastuzumab in hormone refractory, hormone receptor (HR)-positive, HER2-normal metastatic breast cancer (MBC)

10.1158/1538-7445.sabcs16-p6-16-03 ◽

2017 ◽

Author(s):

E Paplomata ◽

K Gogineni ◽

J Meisel ◽

C Santa-Maria ◽

L Yuan ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Hormone Receptor ◽

Metastatic Breast ◽

Phase 2 ◽

Phase 2 Trial ◽

Hormone Refractory

Download Full-text